Clinical Trials
9 trialsNCT07623798 2026-06-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Not yet recruiting
NCT07624513 2026-06-03
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 3 Not yet recruiting
NCT07285239 2026-05-18
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT07569757 2026-05-08
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT07393282 2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT07181239 2025-09-18
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Keymed Biosciences Co.Ltd
Phase 3 Not yet recruiting
NCT06580223 2025-07-18
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Not yet recruiting
NCT06742138 2024-12-19
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06314698 2024-03-18
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
RenJi Hospital
Phase 3 Not yet recruiting